2014 Drug Pricing Packaging 
Pharmaceutical Technology
JUNE 6, 2025
Founded in 2014, Sydnexis is a US-based company and has recently concluded the three-year primary endpoint of its Phase III trial of the low-dose atropine formulation. Give your business an edge with our leading industry insights.
Pharmaceutical Technology
JULY 11, 2025
According to a November 2024 GlobalData report, per-trial costs have risen steadily since 2014, with single country trials increasing by 2.9% 9 Rising direct trial costs and lost revenue due to delayed approval are key factors driving the total cost of bringing a new drug to market to a staggering $2.3bn. per year over this decade.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Safe Biologics
NOVEMBER 12, 2023
6 would prevent the HHS Secretary from requiring a switching study as part of the data package to receive the interchangeable designation. Pitts: The IRA makes the risks of developing new drugs too high On September 14th, an op-ed by former FDA Associate Commissioner Peter J. However, S.6 ASBM surveys of U.S.
HealthPartners
MAY 6, 2021
According to Pew Charitable Trust, between 2014 and 2016, PBMs more than doubled the income they earned from spread pricing (markups on drugs) and fees from drug manufacturers. Where do drug rebates go? There’s a lot of room for loopholes in pharmacy benefit contracts , particularly those from traditional PBMs.
Expert insights. Personalized for you.
Let's personalize your content